US009511114B2

(12) **United States Patent**
Hofmann et al.

(10) **Patent No.: US 9,511,114 B2**
(45) **Date of Patent: Dec. 6, 2016**

(54) **NEUROTOXINS EXHIBITING SHORTENED BIOLOGICAL ACTIVITY**

(71) Applicant: **MERZ PHARMA GmbH & CO. KGaA**, Frankfurt am Main (DE)

(72) Inventors: **Fred Hofmann**, Potsdam (DE); **Jurgen Frevert**, Berlin (DE)

(73) Assignee: **MERZ PHARMA GmbH & CO. KGaA**, Frankfurt am Main (DE)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/886,485**

(22) Filed: **Oct. 19, 2015**

(65) **Prior Publication Data**

US 2016/0030511 A1 Feb. 4, 2016

Related U.S. Application Data

(60) Continuation of application No. 14/056,247, filed on Oct. 17, 2013, now Pat. No. 9,193,771, which is a division of application No. 13/381,533, filed as application No. PCT/EP2010/059398 on Jul. 1, 2010, now Pat. No. 8,586,329.

(60) Provisional application No. 61/270,198, filed on Jul. 2, 2009.

(30) **Foreign Application Priority Data**

Jul. 2, 2009 (EP) 09164365

(51) **Int. Cl.**

A61K 39/08	(2006.01)
A61K 38/00	(2006.01)
C07K 14/00	(2006.01)
A61K 38/16	(2006.01)
C07K 14/33	(2006.01)
C12N 9/52	(2006.01)
C07K 16/12	(2006.01)
A61K 8/64	(2006.01)
A61Q 19/00	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 38/164*** (2013.01); ***A61K 8/64*** (2013.01); ***A61K 39/08*** (2013.01); ***A61Q 19/00*** (2013.01); ***C07K 14/33*** (2013.01); ***C07K 16/1282*** (2013.01); ***C12N 9/52*** (2013.01); *A61K 38/00* (2013.01); *C07K 2319/95* (2013.01)

(58) **Field of Classification Search**

CPC combination set(s) only.
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

7,172,764	B2	2/2007	Li et al.
7,211,261	B1	5/2007	Moyer et al.
7,825,233	B2	11/2010	Steward

FOREIGN PATENT DOCUMENTS

WO	WO 02/08268	1/2002
WO	WO 2005/007185	1/2005
WO	WO 2006/020208	2/2006

OTHER PUBLICATIONS

Belizario, Science vol. 9, p. 210-220, 2008.
Chen, Infect Immun. vol. 66, No. 6, p. 2420-2425, 1998.
Couesnon, Microbiology, vol. 152, p. 759-779, 2006.
Dasgupta Bibhuti, R. The Journal of General and Applied Microbiology, vol. 54, No. 1, p. 1-8, Feb. 1, 2006.
Dressler, Mov. Disorder. vol. 20, p. 1617-1619, 2005.
Eleopra, Neurosci Lett. 13, vol. 256, No. 3, p. 135-138, 1998.
Eleopra, Neurosci Lett. 14, vol. 224, No. 2, PT 91-94, 1997.
European Search Report for EP09164365 of Aug. 11, 2009.
Falnes, P.O.. et al, EMBO Journal, vol. 17, No. 2, p. 615-625, Jan. 1, 1998.
Fischer, PNAS, vol. 104, p. 10447-10452, 2007.
Foran, J. Biol. Chem., vol. 278, No. 2, p. 1363-1371, 2003.
Gupta Pradeep K, et al. PLoS One 2008, vol. 3, No. 9, p. E3130, Jan. 1, 2008
Ibanez, C., et al., FEBS Letters, vol. 578, No. 1-2, p. 121-127, Dec. 3, 2004.
International Preliminary Report on Patentability for PCT/EP2010/059398 of Jan. 12, 2012.
International Search Report for PCT/EP2010/059398 of Oct. 4, 2010.
Jost, Drugs, vol. 67, p. 669-683, 2007.
Keller, Neuroscience, vol. 139, p. 629-637, 2006.
Krieglstein, Eur J. Biochem, vol. 188, p. 39-45, 1990.
Krieglstein, Eur J. Biochem, vol. 202, p. 41-51, 1991.
Krieglstein, J. Protein Chem., vol. 13, p. 49-57, 1994.
Oyler, G.A., et al, Toxicon, vol. 51, p. 17, Jun. 1, 2008.
Pearce, Toxicol Appl Pharmacol. vol. 128, p. 69-77, 1994.
Rechsteiner, TIBS, vol. 21, p. 267-271, 1996.
Rogers, Science, vol. 234, p. 364-368, 1986.
Sloop, Neurology, vol. 49, No. 1, p. 189-194, 1997.
Suzuki, T., et al, EMBO Journal, vol. 18, No. 21, p. 6017-6026, Jan. 1, 1999.
Washbourne, J. Physiol Paris, vol. 92, No. 2, p. 135-139, 1998.
Sathyamoorthy, et al. "Reductive methylation of lysine residues of botulinum neurotoxin types A and B", Molecular and Cellular Biochemistry 83:65-72, 1986.

Primary Examiner — Padma V Baskar
(74) *Attorney, Agent, or Firm* — Hueschen and Sage

(57) **ABSTRACT**

The present invention relates to the pharmaceutical field. Specifically, it contemplates a polynucleotide encoding a Neurotoxin polypeptide exhibiting a reduced duration of biological effect in a subject, wherein the polypeptide comprises at least one degradation signal in the light chain as well as vectors and host cells comprising the polynucleotide, polypeptides encoded thereby and antibodies specifically binding to the polypeptides. Moreover, the invention relates to medicaments comprising the polynucleotides and polypeptides as well as specific therapeutic applications thereof. Furthermore, the present invention contemplates methods for the manufacture of the polypeptides and medicaments.

5 Claims, No Drawings